Alzheimer's and Leqembi: What we Know So Far
Alzheimer’s disease is a progressive neurodegenerative disease that is the most common cause of dementia. It is characterized by the loss of neurons and synapses in the brain, which leads to a decline in cognitive function and memory. Leqembi (lecanemab) is a monoclonal antibody that has been shown to slow the progression of Alzheimer’s disease in clinical trials. It was approved by the FDA on June 6, 2023, for the treatment of people with mild cognitive impairment or early Alzheimer’s disease. Leqembi works by binding to beta-amyloid, a protein that forms plaques in the brains of people with Alzheimer’s disease. These plaques are thought to play a role in the progression of the disease. By binding to beta-amyloid, Leqembi helps to reduce the amount of plaque in the brain and slow the progression of the disease. In clinical trials, Leqembi was shown to reduce the rate of cognitive decline in people with Alzheimer’s disease by 27%. It was also shown to be safe and well-tolerated. Leqembi is the first FDA-approved drug that has been shown to slow the progression of Alzheimer’s disease. It is a significant breakthrough in the treatment of this devastating disease. However, there has been some controversy with the FDA’s approval of Leqembi. First, some experts have raised concerns about the clinical trials that were conducted to test Leqembi. The trials were relatively small, and they were not designed to show whether Leqembi could improve patients’ quality of life or help them to live longer. Second, Leqembi has been associated with some serious side effects, including brain swelling and bleeding. These side effects are more common in people who have two copies of the APOE4 gene, a gene that is linked to Alzheimer’s disease. Third, Leqembi is very expensive. The drug is expected to cost around $28,000 per year. This has raised concerns about access to the drug, particularly for people who are not insured or who have limited financial resources. Despite these concerns, some experts believe that Leqembi represents a significant advance in the treatment of Alzheimer’s disease. They argue that the drug can provide meaningful benefits to patients, even if it does not cure the disease. Overall, the FDA’s approval of Leqembi is a complex issue with pros and cons. It is important to weigh the potential benefits of the drug against the risks and costs before making a decision about whether to use it. If you have any concerns about Leqembi, please talk to your doctor. They can help you to weigh the risks and benefits of the drug and decide if it is right for you. Thanks for listening to Quiet Please. Remember to like and share wherever you get your podcasts.
This content was created in partnership and with the help of Artificial Intelligence AI.
© 2026 Inception Point AI · more info
Artwork and data is from the podcast’s open RSS feed; we link directly to audio · Read our DMCA procedureQuiet. Please
See more
This podcast may use tracking and attribution and dynamic content insertion
Stats: Statistics are produced by Megaphone to help Alzheimer's and Leqembi: What we Know So Far to understand how many downloads it is getting, or how many people are listening. Your device’s IP address and user agent is used to help calculate this figure. Megaphone is IAB v2 certified. Here is more detail about podcast statistics.
Tracking and attribution: Megaphone or its partners may connect the fact you listened to this podcast to an action elsewhere on the internet. For example - it may spot a device that downloaded an episode of Alzheimer's and Leqembi: What we Know So Far later visited the website of an advertiser; or it may track that a device that listened to Alzheimer's and Leqembi: What we Know So Far also listened to a different show. This form of attribution is used to measure advertising effectiveness.
Dynamic content insertion: Megaphone may use limited data that they know about you - the device you’re using, the approximate location you’re in, or other data that can be derived from this, like the current weather forecast for your area - to change parts of the audio. Alzheimer's and Leqembi: What we Know So Far may do this for advertising or for other forms of content, like news stories.
Alzheimer's and Leqembi: What we Know So Far is able to use the above tools since its podcast host or measurement company offers this service. It doesn’t mean that this individual podcast uses them, or has access to this functionality. We use open data.
Listen and follow
Apple PodcastsInformation for podcasters
- This podcast previously hosted on Spreaker (until May 2026), and now hosts with Megaphone. See changes across podcasting.
- There is a different RSS feed listed in the Podcast Index (here) and Apple Podcasts (here). Our systems normally pull RSS feed addresses from Apple Podcasts; and it should normally match what’s in the Podcast Index.
- This podcast appears to be missing from Truefans, Podcast Index, iVoox, and Luminary. We list all the podcast directories to be in.
- Validate this podcast’s RSS feed with Livewire, Truefans or CastFeedValidator